ACLARIS THERAPEUTICS INC (ACRS)
US00461U1051 - Common Stock
We assign a fundamental rating of 4 out of 10 to ACRS. ACRS was compared to 194 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ACRS as it has an excellent financial health rating, but there are worries on the profitability. ACRS is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ACRS has reported negative net income.
In the past year ACRS has reported a negative cash flow from operations.
ACRS had negative earnings in each of the past 5 years.
ACRS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a decent Return On Assets value of -20.29%, ACRS is doing good in the industry, outperforming 63.02% of the companies in the same industry.
The Return On Equity of ACRS (-28.43%) is better than 66.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.29% | ||
| ROE | -28.43% | ||
| ROIC | N/A |
ROA(3y)-38.38%
ROA(5y)-70.27%
ROE(3y)-48.78%
ROE(5y)-102.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 53.53%, ACRS is in the better half of the industry, outperforming 62.50% of the companies in the same industry.
In the last couple of years the Gross Margin of ACRS has grown nicely.
ACRS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y26.47%
GM growth 5Y7.32%
2. Health
2.1 Basic Checks
ACRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACRS has been increased compared to 1 year ago.
ACRS has more shares outstanding than it did 5 years ago.
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -2.76, we must say that ACRS is in the distress zone and has some risk of bankruptcy.
ACRS's Altman-Z score of -2.76 is in line compared to the rest of the industry. ACRS outperforms 41.15% of its industry peers.
ACRS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.76 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
A Current Ratio of 7.03 indicates that ACRS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.03, ACRS is in the better half of the industry, outperforming 75.52% of the companies in the same industry.
A Quick Ratio of 7.03 indicates that ACRS has no problem at all paying its short term obligations.
ACRS's Quick ratio of 7.03 is fine compared to the rest of the industry. ACRS outperforms 77.08% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.03 | ||
| Quick Ratio | 7.03 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 68.29% over the past year.
The Revenue has grown by 26.36% in the past year. This is a very strong growth!
ACRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.42% yearly.
EPS 1Y (TTM)68.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%73.17%
Revenue 1Y (TTM)26.36%
Revenue growth 3Y68.95%
Revenue growth 5Y38.42%
Sales Q2Q%-53.18%
3.2 Future
ACRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.43% yearly.
Based on estimates for the next years, ACRS will show a quite strong growth in Revenue. The Revenue will grow by 11.78% on average per year.
EPS Next Y49.06%
EPS Next 2Y21.18%
EPS Next 3Y12.03%
EPS Next 5Y13.43%
Revenue Next Year-22.04%
Revenue Next 2Y-27.03%
Revenue Next 3Y-19.05%
Revenue Next 5Y11.78%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ACRS. In the last year negative earnings were reported.
Also next year ACRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ACRS's earnings are expected to grow with 12.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.18%
EPS Next 3Y12.03%
5. Dividend
5.1 Amount
No dividends for ACRS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACLARIS THERAPEUTICS INC
NASDAQ:ACRS (11/20/2024, 8:05:06 PM)
Premarket: 3.94 -0.02 (-0.51%)3.96
-0.63 (-13.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap282.86M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.29% | ||
| ROE | -28.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.53% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.03 | ||
| Quick Ratio | 7.03 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)68.29%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y49.06%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)26.36%
Revenue growth 3Y68.95%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y